The Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market is estimated to be valued at US$ 1.98 billion in 2027 and is expected to exhibit a CAGR of 31.1% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights. Market Overview: Transthyretin amyloid cardiomyopathy (ATTR-CM) is a rare, progressive heart muscle disease caused by the buildup of abnormal deposits of amyloid fibrils comprised of misfolded transthyretin protein in the heart. ATTR-CM impairs the heart's ability to pump blood and can lead to heart failure. Current treatments for ATTR-CM include anticoagulants, diuretics, and beta-blockers to manage symptoms as there are limited cure options. Market Dynamics: The ATTR-CM treatment market is expected to witness high growth over the forecast period, owing to increasing drug approvals and launch of novel therapies. Growing availability of ATTR-CM treatments is one of the major factors driving the market growth. Until recently, there were limited therapeutic options for ATTR-CM. However, approval and launch of therapies such as Vyndaqel and Vyndamax by Pfizer in 2019 expanded treatment options. Furthermore, increasing R&D investment in ATTR-CM treatment is fueling the pipeline. Several pharmaceutical companies are actively engaged in developing new ATTR-CM therapies. For instance, in March 2022, Eidos Therapeutics announced positive results from Phase 3 ATTRibute-CM study evaluating acoramidis in transthyretin amyloid cardiomyopathy. Segment Analysis The global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market is segmented based on type and treatment. Based on type, it is segmented into hereditary ATTR-CM and wild-type ATTR-CM. The hereditary ATTR-CM segment is dominating currently due to the large patient pool suffering from this genetic disease globally. PEST Analysis Political: Government agencies are providing funding for research on novel drugs for ATTR-CM treatment which is promoting market growth. Economic: Developed regions like North America have higher healthcare spending which is driving clinical trials and drug approvals in these regions. Social: Increasing awareness through patient advocacy groups about ATTR-CM is encouraging development of new treatment options. Technological: Companies are focusing on RNAi technologies and antisense oligonucleotides for developing potential therapies to halt or reverse disease progression. Key Takeaways The Global Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market Size is expected to witness high growth, exhibiting CAGR of 31.1% over the forecast period, due to increasing research and development investments leading to new product approvals. North America dominates the global market currently owing to the high disease prevalence and supportive regulatory environment for clinical trials in the region. The approval of disease modifying drugsVyndaqel and Vyndamax has boosted the regional market growth. Key players operating in the Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Treatment Market are Pfizer Inc., GlaxoSmithKline Plc., Eidos Therapeutics, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Prothena Corporation plc, Intellia Therapeutics, Inc., and Corino Therapeutics, Inc. Major players are focusing on development of RNAi-based therapies, antisense oligonucleotides and gene therapy for ATTR-CM. Read More- https://www.newsstatix.com/transthyretin-amyloid-cardiomyopathy-attr-cm-treatment-market-growth-analysis-and-value/
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. Archives
April 2024
Categories
All
|